Gena Wang
Stock Analyst at Barclays
(3.30)
# 1,029
Out of 5,090 analysts
238
Total ratings
45.16%
Success rate
3.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $36.38 | +37.44% | 7 | Nov 24, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $94 → $90 | $28.13 | +219.94% | 7 | Nov 13, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $10.70 | +208.41% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $27.70 | -9.75% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $9.61 | +45.68% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.50 | +101.65% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $77.26 | -11.98% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $22.26 | -10.15% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $455.48 | -9.11% | 18 | Nov 4, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $10 → $9 | $5.77 | +55.98% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $7.59 | +18.58% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $458.12 | +15.04% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $81.68 | +16.31% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $53.40 | +49.81% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $4.74 | +68.78% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $82 | $65.67 | +24.87% | 4 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $24.34 | -30.16% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $13.16 | +181.16% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $71.63 | -13.44% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $56.88 | -1.55% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $27.09 | -22.48% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $6.50 | +376.92% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.42 | +23.97% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $26.69 | -66.28% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $7.13 | +250.63% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.65 | +108.09% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $5.30 | +69.81% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $4.88 | +5,541.03% | 1 | Jan 6, 2017 |
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $36.38
Upside: +37.44%
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $94 → $90
Current: $28.13
Upside: +219.94%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $10.70
Upside: +208.41%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $27.70
Upside: -9.75%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $9.61
Upside: +45.68%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.50
Upside: +101.65%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $77.26
Upside: -11.98%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $22.26
Upside: -10.15%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $455.48
Upside: -9.11%
Solid Biosciences
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $5.77
Upside: +55.98%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $7.59
Upside: +18.58%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $458.12
Upside: +15.04%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $81.68
Upside: +16.31%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $53.40
Upside: +49.81%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $4.74
Upside: +68.78%
Oct 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $65.67
Upside: +24.87%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $24.34
Upside: -30.16%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $13.16
Upside: +181.16%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $71.63
Upside: -13.44%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $56.88
Upside: -1.55%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $27.09
Upside: -22.48%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $6.50
Upside: +376.92%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.42
Upside: +23.97%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $26.69
Upside: -66.28%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $7.13
Upside: +250.63%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.65
Upside: +108.09%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $5.30
Upside: +69.81%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $4.88
Upside: +5,541.03%